Recent Publications

Recent Publications by RPMI Members as First or Last Author

Comparison of postprocessing metrics in multimetabolic APT-weighted CEST and 2-deoxy-D-glucose-CEST-MRI for differentiating breast cancer subtypes in a murine model.

Prinz D, Bartsch SJ, Friske J, Krššák M, Laimer-Gruber D, Helbich TH, Pinker K. Eur Radiol Exp. 2026 Jan 19;10(1):5. doi: 10.1186/s41747-025-00665-z.

Phenotyping extracellular vesicles and their serotonin transporter cargo in major depressive disorder.

Zadka Ł, Eggerstorfer B, Buzalewicz I, Vraka C, Rusak A, Godbersen GM, Opalińska A, Unterholzner J, Ulatowska-Jarża A, Philippe C, Haczkiewicz-Leśniak K, Silberbauer LR, Murgaš M, Nics L, Hahn A, Hacker M, Gomułkiewicz A, Rujescu D, Podhorska-Okołów M, Lanzenberger R, Gryglewski G.

Affect Disord. 2025 Nov 15;389:119740. doi: 10.1016/j.jad.2025.119740

Enhanced vascular inflammation in patients with advanced prostate cancer receiving hormone therapy.

Einspieler H, Muin D, Langrate IK, Schmitl S, Spielvogel CP, Fueger BJ, Li X, Kramer G, Shariat SF, Hacker M, Rasul S. Eur J Nucl Med Mol Imaging. 2025 Dec;53(1):557-564. doi: 10.1007/s00259-025-07409-6.

Enhancing clinical safety in radiation oncology: A data-driven approach to risk management.

Sölkner L, Georg D, Wolff U, Renner A, Widder J, Heilemann G. Z Med Phys. 2025 Nov;35(4):408-415. doi: 10.1016/j.zemedi.2025.02.003.

In vivo evidence of functional OATP2B1 activity in human skeletal muscle using [¹¹C]erlotinib PET.

Jackwerth M, Mairinger S, Hacker M, Tournier N, Zeitlinger M, Langer O. Eur J Pharm Sci. 2026 Jan 14;218:107441. doi: 10.1016/j.ejps.2026.107441.

Evaluating methodological constraints in PET imaging of neuropeptide Y2 receptors with N-[¹¹C]-methyl-(R)-JNJ-31020028 in brains of C57BL/6J mice.

Bamminger K, Fernandes EFA, Zachhuber L, Lopez-Martinez I, Kuntner C, Langer O, Mairinger S, Christoffersen BØ, Hacker M, Wanek T. EJNMMI Radiopharm Chem. 2025 Dec 5;11(1):1. doi: 10.1186/s41181-025-00407-x.

Spatial imaging features derived from SUVmax location in resectable NSCLC are associated with tumor aggressiveness.

Jiang Z, Spielvogel C, Haberl D, Yu J, Krisch M, Szakall S, Molnar P, Fillinger J, Horvath L, Renyi-Vamos F, Aigner C, Dome B, Lang C, Megyesfalvi Z, Kenner L, Hacker M. Eur J Nucl Med Mol Imaging. 2026 Feb;53(3):1458-1468. doi: 10.1007/s00259-025-07528-0.

The metabolic organ connectome: A novel approach to measure allostatic load during health-to-disease transition.

Geist BK, Guthrie J, Kertesz H, Kiefer FW, Kulterer OC, Nakuz T, Nics L, Patronas EM, Rendeiro A, Vraka C, Yu J, Grünert S, Hacker M. Med. 2025 Dec 12;6(12):100881. doi: 10.1016/j.medj.2025.100881.

Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [¹⁸F]PARPi and [⁶⁸Ga]PSMA PET/CT?

Einspieler H, Ofner H, Ozenil M, Spielvogel CP, Langrate IK, Hassler MR, Nics L, Bamminger K, Baltzer PAT, Shariat SF, Hacker M, Kramer G, Rasul S. Eur J Nucl Med Mol Imaging. 2026 Jan;53(2):812-823. doi: 10.1007/s00259-025-07448-z.

Unambiguous analytical separation and improved syntheses of [¹¹C]acetate and [¹¹C]acetoacetate.

Bamminger K, Nics L, Hacker M, Philippe C, Ozenil M. EJNMMI Radiopharm Chem. 2025 Dec 26;11(1):5. doi: 10.1186/s41181-025-00412-0.

FAPI Tracer en Vogue: Evaluating [⁶⁸Ga]Ga-DATA^5m.SA.FAPi for Molecular Imaging of Pulmonary Fibrosis.

Weissenböck V, Schlederer M, Bakiri L, Schaffenrath J, Wagner EF, Rösch F, Hacker M, Kenner L, Philippe C. Pharmaceuticals (Basel). 2025 Dec 23;19(1):34. doi: 10.3390/ph19010034.

Artificial intelligence-enabled opportunistic identification of immune checkpoint inhibitor-related adverse events using [¹⁸F]FDG PET/CT.

Spielvogel CP, Lazarevic A, Zisser L, Haberl D, Eseroglou C, Beer L, Hacker M, Calabretta R. Eur J Nucl Med Mol Imaging. 2025 Nov;52(13):4963-4971. doi: 10.1007/s00259-025-07364-2.

Noninvasive in vivo deoxycytidine kinase (dCK)-PET identifies tumor-draining lymph nodes upon immune checkpoint inhibitor therapy.

Philippe C, Cotton J, Bowden GD, Pöschel S, Knopf P, Schörg B, Gonzalez-Menendez I, Sonanini D, Flatz L, Allen-Auerbach M, Radu CG, Czernin J, Quintanilla-Martinez L, Hacker M, Pichler BJ, Maurer A, Kneilling M. Npj Imaging. 2026 Jan 6;4(1):1. doi: 10.1038/s44303-025-00133-8.

[¹⁷⁷Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report.

Langrate IK, Kretschmer-Chott E, Schmitl S, Shariat SF, Hacker M, Kramer G, Rasul S. Wien Klin Wochenschr. 2025 Nov 6. doi: 10.1007/s00508-025-02642-3.

Feasibility of [⁶⁸Ga]Ga-FAPI PET Molecular Imaging in Atherosclerosis Compared with [¹⁸F]FDG in Oncological Patients.

Calabretta R, Atli E, Geist BK, Muin D, Zisser L, Spielvogel CP, Falkenbach C, Kretschmer-Chott E, Schmitl S, Bergler-Klein J, Li X, Binder P, Hacker M. Diagnostics (Basel). 2025 Dec 5;15(24):3099. doi: 10.3390/diagnostics15243099.

Impact of disease-modifying therapy on [^99mTc]Tc-DPD SPECT/CT markers in transthyretin cardiac amyloidosis enabled by artificial intelligence.

Spielvogel CP, Köfler M, Jiang Z, Ning J, Yu J, Haberl D, Kronberger C, Poledniczek M, Schmid LM, Kersting D, Ermolaev N, Eslam RB, Auer-Grumbach M, Binder C, Duca F, Nitsche C, Kastner J, Bergler-Klein J, Kammerlander AA, Hengstenberg C, Hacker M, Calabretta R, Rettl R. Eur J Nucl Med Mol Imaging. 2025 Nov 29. doi: 10.1007/s00259-025-07673-6.

PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.

Hartenbach M, Rasul S, Grubmüller B, Kramer G, Baltzer P, Helbich T, Eiber M, Hartenbach S, Grahovac M, Susani M, Mazal P, Wadsak W, Einspieler H, Weber M, Kenner L, Haug AR, Hacker M. J Nucl Med. 2026 Feb 2;67(2):224-231. doi: 10.2967/jnumed.125.270404.
 

* * *
 

Li Q, Ali Z, Zakian C, di Pietro M, Honing J, O'Donovan M, Flisikowski K, Sarantos V, Pierre G, Gloriod J, Drexler W, Ntziachristos V. Tethered optoacoustic and optical coherence tomography capsule endoscopy for label-free assessment of Barrett's oesophageal neoplasia. Nature Biomed Eng. 2025. doi: 10.1038/s41551-025-01462-0. Epub ahead of print. PMID: 40770504.

Phenotyping extracellular vesicles and their serotonin transporter cargo in major depressive disorder.
Zadka Ł, Eggerstorfer B, Buzalewicz I, Vraka C, Rusak A, Godbersen GM, Opalińska A, Unterholzner J, Ulatowska-Jarża A, Philippe C, Haczkiewicz-Leśniak K, Silberbauer LR, Murgaš M, Nics L, Hahn A, Hacker M, Gomułkiewicz A, Rujescu D, Podhorska-Okołów M, Lanzenberger R, Gryglewski G. J Affect Disord. 2025 Nov 15;389:119740. doi: 10.1016/j.jad.2025.119740. Epub 2025 Jun 21. PMID: 40550277

Wanek T, Teuter M, Balakrishnan A, Ross TL, Bengel FM, Ott M, Bankstahl M, Bankstahl JP. [18F]FDG-PET provides insights into the liver-brain axis and confirms SUVgluc as a surrogate for MRGlu in a mouse model of liver fibrosis. Nucl Med Biol. 2025 Sep 4;150-151:109095. doi: 10.1016/j.nucmedbio.2025.109095. Epub ahead of print. PMID: 40913906.

Identifying signatures of image phenotypes to track treatment response in liver disease. Perkonigg M, Bastati N, Ba-Ssalamah A, Mesenbrink P, Goehler A, Martic M, Zhou X, Trauner M, Langs G. Artif Intell Med. 2025 Oct;168:103223. doi: 10.1016/j.artmed.2025.103223. Epub 2025 Jul 21. PMID: 40700864

Abdarahmane I, Wolf L, Kuess P, Heilemann G, Stocchiero S, Knäusl B, Feinerer I, Zeilinger M, Georg D. An open-source irradiation and data-handling framework for pre-clinical ion-beam research. Z Med Phys. 2025 Sep 1:S0939-3889(25)00114-X. doi: 10.1016/j.zemedi.2025.08.002. Epub ahead of print. PMID: 40897599.  

Gutschmayer S, Yu J, Geist BK, Özer Ö, Reiterits B, Ferrara D, Pires M, Rausch I, Ibeschitz H, Karanikas G, Sundar LKS, Nics L, Chalampalakis Z, Muin D, Langsteger W, Hacker M, Beyer T. Whole-Body [¹⁸F]FDG-PET/CT Imaging of Healthy Controls: Test/Retest Data for Systemic, Multi-Organ Analysis. Sci Data. 2025 Oct 29;12(1):1707. doi: 10.1038/s41597-025-05997-4. PMID: 41162425; PMCID: PMC12572201.

Response to comments regarding our study on BPE in CEM "No, background parenchymal enhancement (BPE) is a problem in contrast-enhanced mammography (CEM)".
Bechyna S, Santonocito A, Pötsch N, Clauser P, Helbich TH, Baltzer PAT. Eur J Radiol. 2025 Oct;191:112305. doi: 10.1016/j.ejrad.2025.112305. Epub 2025 Jul 8. PMID: 40651114

Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth. Fesiuk A, Pölöske D, de Araujo ED, Frere GA, Wright TB, Tin G, Raouf YS, Olaoye OO, Park JS, Blavet N, Tichý B, Schlederer M, Högler S, Wolf M, Philippe C, Aksoy O, Varady A, Mata AM, Varenicja M, Szabó B, Weiss T, Wasinger G, Redmer T, Neubauer HA, Susani M, Spielvogel CP, Ning J, Dahlhoff M, Schepelmann M, Kennedy R, Moriggl R, Brown G, Persson J, Gerner C, Bystry V, Hollóczki O, Heery DM, Gunning PT, Merkel O, Hantusch B, Kenner L. Mol Cancer. 2025 Oct 14;24(1):256. doi: 10.1186/s12943-025-02451-2. PMID: 41088246

Heilemann G, Rotunno G, Krainz L, Gili F, Müller C, Meiburger KM, Georg D, Widder J, Drexler W, Liu M, Waldstein C. Optical Coherence Tomography Angiography (OCTA) Captures Early Micro-Vascular Remodeling in Non-Melanoma Skin Cancer During Superficial Radiotherapy: A Proof-of-Concept Study. Diagnostics (Basel). 2025 Oct 24;15(21):2698. doi: 10.3390/diagnostics15212698. PMID: 41225992; PMCID: PMC12607523.

Fazekas B, Aresta G, Seebock P, Mai J, Schmidt-Erfurth U, Bogunovic H. SD-RetinaNet: Topologically Constrained Semi-Supervised Retinal Lesion and Layer Segmentation in OCT. IEEE Trans Med Imaging. 2025 Oct 1;PP. doi: 10.1109/TMI.2025.3615240. Epub ahead of print. PMID: 41032557.